TLTingting Lin

Tingting Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tingting Lin has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Hu Zhao

    Fuzong Clinical Medical College of Fujian Medical University, 900TH Hospital of the Joint Logistics Support Force, Fuzhou, China

    1 shared publication
  • Huiyue Dong

    Fujian Key Laboratory of Transplant Biology, Affiliated Dongfang Hospital, Xiamen University School of Medicine, Fuzhou, 350025, Fujian Province, China

    1 shared publication
  • Jin Chen

    Institute of Clinical Medicine, The Second Affiliated Hospital of Hainan Medical University, Haikou, China

    1 shared publication
  • Jinquan Cai

    Department of Urology, The 900th Hospital of the Joint Logistics Team (the Former Fuzhou General Hospital), Fujian Medical University, Fuzhou 350025, China. 156 Xi’er Huan Bei Road, Fuzhou, 350025, Fujian Province, China

    1 shared publication
  • Lianghu Huang

    Fujian Key Laboratory of Transplant Biology, Affiliated Dongfang Hospital, Xiamen University School of Medicine, Fuzhou, 350025, Fujian Province, China

    1 shared publication
  • Linhui Xie

    Department of Clinical Medicine, Fujian Health Vocational and Technical College, Fuzhou, 350101, Fujian Province, China

    1 shared publication

Latest Publications

  • Open Access

    Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs

    by Tingting Lin, Qun Ren, Weimin Zuo, Ruxue Jia, Linhui Xie, Rong Lin, Hu Zhao, Jin Chen, Yan Lei, Ping Wang, et al.

    Deregulated ErbB signaling plays an important role in tumorigenesis of pancreatic cancer. However, patients with pancreatic cancer benefit little from current existed therapies targeting the ErbB signaling. Here, we explore the potential anti-tumor activity of Valproic acid against pancreatic cancer via targeting ErbB family members. Cell viability assay and apoptosis evaluation were carried out to determine the efficacy of VPA on pancreatic cancer cells. Western blot analyses were performed to determine the expression and activation of proteins. Apoptosis enzyme-linked immunosorbent assay was used to quantify cytoplasmic histone associated DNA fragments. Lentiviral expression system was used to introduce overexpression of exogeneous genes or gene-targeting short hairpin RNAs (shRNAs). qRT-PCR was carried out to analyze the mRNAs and miRNAs expression levels. Tumor xenograft model was established to evaluate the in vivo anti-pancreatic cancer activity of VPA. VPA preferentially inhibited cell proliferation/survival of, and induced apoptosis in EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer cells within its clinically achievable range [40~100 mg/L (0.24~0.6 mmol/L)]. Mechanistic investigations revealed that VPA treatment resulted in simultaneous significant down-regulation of EGFR, ErbB2, and ErbB3 in pancreatic cancer cells likely via induction of ErbB family members-targeting microRNAs. Moreover, the anti-pancreatic cancer activity of VPA was further validated in tumor xenograft model. Our data strongly suggest that VPA may be added to the treatment regimens for pancreatic cancer patients with co-overexpression of the ErbB family members.